Compare Kaltura Inc (KLTR) vs Novavax Inc (NVAX) Price & Performance

Kaltura (KLTR) trades at $1.385, down 0.36% with a bullish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue stabilizing around $180M. Recent industry recognition includes being named a Leader in virtual event platforms by Forrester and Aragon Research in June 2026. Operating cash flow turned positive in Q1 2026 for the first time in company history, though net margins remain negative at -8.25%.

While technical indicators suggest near-term strength, fundamental challenges persist with negative ROE of -107.84% and high P/B ratio of 44.85. Analyst consensus leans bullish with 44% buy ratings, but profitability concerns and competitive pressures in the digital experience platform space warrant caution. The upcoming Q2 2026 earnings on August 5 will be critical for validating the company's turnaround trajectory.

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.